The global regenerative medicine industry is rapidly on the rise. Factors impacting the regenerative medicine industry are growing development in healthcare technologies, growing the prevalence of chronic disorders and growing advances in stem cell science are driving market expansion.
According to MRFR, the Global regenerative medicine market 2020 is touted to mature at the CAGR of about 25.4% over the review period (from 2016 to 2022).
In addition to these aspects, the success in the market is due to major corporations focusing on oncology & age-related degenerative diseases. Therefore, the industry is experiencing a large pipeline of drugs in clinical trials that are supposed to effectively fuel revenue generation.
The global demand for regenerative medicine was segmented on the basis of material consisting of synthetic products, genetically engineered products, pharmaceuticals, biologically derived materials and other materials. The industry is segmented into stem cell biology, cell therapy, tissue engineering and others depending on the therapies. In addition, the market is segmented according to application into cord blood, oncology, urology, orthopedics, neurology, dermatology, neurological, orthopedics and others.
few of the leading players in the global regenerative medicine at the vanguard of the competition and are profiled in MRFR Research are Cook Biotech Inc. (U.S.), Organogenesis Inc. (U.S.), Vericel Corporation (U.S.), Stryker Corporation (U.S.), NuVasive, Inc. (U.S.), Medtronic (Ireland), C.R. Bard (U.S.), RTI surgical (U.S.), Baxter International, Inc. (U.S.), Advanced Cell Technology (U.S.), CryoLife (U.S.), Sanofi (France), BioMimetic Therapeutics (U.S.), StemCells Inc. (U.S.), Acelity (KCI Concepts) (U.S.), Osiris Therapeutics, Inc. (U.S.), Integra LifeSciences (U.S.), LifeCell Kinetic Concepts (U.S.) and others are